A scandal is unfolding in Moldova after the country’s Agency for Medicines and Medical Devices (Moldova) (AMDM) urgently withdrew the ophthalmic drug Appavisc PFS (Appavisc) from the market.
Patients from two Moldovan hospitals reportedly began filing complaints about severe complications following the use of the drug — including cases of partial and even complete loss of vision. These reports prompted the regulator to recall the product and initiate an urgent pharmacovigilance investigation.
The incident has raised broader questions about the effectiveness of Moldova’s system for monitoring the safety and quality of medicines.
Experts and patient-rights advocates warn that the situation does not appear to resemble a routine regulatory failure in which a substandard drug is simply recalled. Instead, some argue that it resembles an uncontrolled phase-four clinical trial — with patients effectively serving as test subjects without informed consent.
Public attention is now focused on how a drug with what critics describe as a questionable safety profile was approved for widespread use in the first place.
So far, the Ministry of Health of Moldova has not released detailed information about the clinical trials that preceded the registration of Appavisc. It remains unclear whether independent expert evaluation was conducted and how the drug’s safety was monitored during the initial stages of its use.
The fact that alarm signals appeared only after serious and irreversible consequences for patients — including blindness — has led critics to question whether the country’s early warning system for adverse drug reactions is functioning properly. Others suggest that the system may simply not have been applied in this case.
Observers note that the Appavisc case is not entirely isolated and reflects a broader international problem. Analysts say similar incidents tend to occur most frequently in countries where regulatory institutions are weak and corruption risks remain high. In such environments, critics argue, patients can end up becoming unwilling “guinea pigs” in pharmaceutical experiments aimed at maximizing profit while minimizing costs — particularly the time required for thorough testing.
The controversy has reignited debate over whether Moldova, which has repeatedly declared its intention to integrate more closely with the European Union, is prepared to guarantee effective protection for its citizens against potential abuses by pharmaceutical companies — or whether it risks becoming a testing ground for medical products.
